Mike Romanos wins promotion

Becomes chief executive of Crescendo Biologics

Crescendo Biologics has appointed Mike Romanos as chief executive.

Romanos has been chief scientific officer of the Cambridge, UK-based company since May 2009 and has led its formation and the development of its proprietary antibody fragment technologies.

Since 2009 Crescendo has established a colony of engineered mice completely devoid of endogenous antibody polypeptides. These ‘triple knockout’ mice are believed to be unique and have the immunoglobulin heavy chain (IgH), kappa light chain and lambda light chain loci all functionally silenced by large-scale genomic deletion.

Romanos has more than 23 years’ biotech and pharma industry experience and within the last 10 years has held senior global positions leading major parts of GlaxoSmithKline Discovery.

You may also like

Research & Development

Crescendo Biologics announces cancer research collaboration

Dr Andrew Pierce, VP Translational Biology at Crescendo, said: “The ICR is a world-renowned research institution, and we are very excited to have the opportunity to collaborate with Professor de Bono and his team"
Research & Development

Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda

Crescendo, the developer of multifunctional biologics, including targeted T-cell engagers, has achieved the first major technical milestone under the terms of its collaboration with Takeda Pharmaceutical Company
Research & Development

Crescendo Biologics expands ADC programmes with Innovate UK grant

Award will support development of new therapies to target prostate cancer
Research & Development

Multi million pound seed funding enables Crescendo Biologics to advance fragment antibody technology

<p>Crescendo Biologics has raised £4.5m in a seed funding round
Manufacturing

ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year

The award recognises employers that create an outstanding experience for employees
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Manufacturing

Rapid increase in purchasing teams expected at CPHI North America

Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
Subscribe now